Tenax Therapeutics, Inc. (TENX)Healthcare | Biotechnology | Chapel Hill, United States | NasdaqCM
15.98 USD
-1.57
(-8.946%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 15.90 -0.08 (-0.080%) ⇩ (July 13, 2026, 6:21 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:33 a.m. EDT
Tenax Therapeutics presents a classic biotech binary trap where the narrative of a 'strong buy' recommendation clashes violently with the reality of the balance sheet and price history. While analysts project a mean target of $35, the company is burning cash aggressively with negative free cash flow and no path to profitability visible in the forward estimates. The most damning indicator is the multi-year price trajectory: despite a recent 70% rebound in 2025, the asset has lost 99.99% of its value over the last nine years, indicating a structural failure in the business model that recent clinical data may not yet have resolved. The options market confirms this skepticism, with traders stacking heavy put protection at strikes far below the current price, effectively betting against any rally. Without a confirmed, transformative catalyst that can reverse the decade-long destruction of shareholder value, the risk of permanent capital loss outweighs the speculative upside. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.192943 |
| AutoETS | 0.197013 |
| MSTL | 0.214267 |
| AutoTheta | 0.249909 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.151 |
| Excess Kurtosis | 0.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 423,872,032 |
| Forward P/E | -11.46 |
| Beta | 0.91 |
| Website | https://www.tenaxthera.com |
As of July 11, 2026, 3:33 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $5-$15) across nearly all expirations, while call volume remains thin and concentrated near the money. This asymmetry suggests a market consensus expecting further volatility or a drop, rather than a breakout toward the $30+ analyst targets.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.9745762 |
| Address1 | 101 Glen Lennox Drive |
| Address2 | Suite 300 |
| All Time High | 21,600,000.0 |
| All Time Low | 2.77 |
| Ask | 20.35 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,885,490 |
| Average Daily Volume3 Month | 944,280 |
| Average Volume | 944,280 |
| Average Volume10Days | 1,885,490 |
| Beta | 0.912 |
| Bid | 12.17 |
| Bid Size | 2 |
| Book Value | 2.288 |
| City | Chapel Hill |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.98 |
| Current Ratio | 14.515 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 17.22 |
| Day Low | 15.89 |
| Display Name | Tenax Therapeutics |
| Dividend Date | 1,519,603,200 |
| Earnings Timestamp End | 1,755,288,000 |
| Earnings Timestamp Start | 1,754,942,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 697,691,392 |
| Eps Current Year | -1.43143 |
| Eps Forward | -1.394 |
| Eps Trailing Twelve Months | -1.41 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.6441 |
| Fifty Day Average Change | 3.3358994 |
| Fifty Day Average Change Percent | 0.2638305 |
| Fifty Two Week Change Percent | 197.45763 |
| Fifty Two Week High | 19.4 |
| Fifty Two Week High Change | -3.42 |
| Fifty Two Week High Change Percent | -0.17628866 |
| Fifty Two Week Low | 5.766 |
| Fifty Two Week Low Change | 10.214 |
| Fifty Two Week Low Change Percent | 1.7714187 |
| Fifty Two Week Range | 5.766 - 19.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 765,466,200,000 |
| Float Shares | 26,482,906 |
| Forward Eps | -1.394 |
| Forward P E | -11.463414 |
| Free Cashflow | -18,746,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00121 |
| Held Percent Institutions | 0.76448 |
| Implied Shares Outstanding | 26,525,159 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,240,000 |
| Last Split Factor | 1:80 |
| Long Business Summary | Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina. |
| Long Name | Tenax Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 423,872,032 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_389766 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -57,907,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 465,516,540 |
| Number Of Analyst Opinions | 8 |
| Open | 17.0009 |
| Operating Cashflow | -38,142,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.44 |
| Phone | 919 855 2100 |
| Post Market Change | -0.07999992 |
| Post Market Change Percent | -0.5006253 |
| Post Market Price | 15.9 |
| Post Market Time | 1,783,981,288 |
| Previous Close | 17.55 |
| Price Eps Current Year | -11.163661 |
| Price Hint | 2 |
| Price To Book | 6.9842653 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.994 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | -1.57 |
| Regular Market Change Percent | -8.94587 |
| Regular Market Day High | 17.22 |
| Regular Market Day Low | 15.89 |
| Regular Market Day Range | 15.89 - 17.22 |
| Regular Market Open | 17.0009 |
| Regular Market Previous Close | 17.55 |
| Regular Market Price | 15.98 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,284,770 |
| Return On Assets | -0.32744 |
| Return On Equity | -0.51707 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 26,525,159 |
| Shares Percent Shares Out | 0.0674 |
| Shares Short | 1,787,937 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 792,041 |
| Short Name | Tenax Therapeutics, Inc. |
| Short Percent Of Float | 0.0682 |
| Short Ratio | 1.46 |
| Source Interval | 15 |
| State | NC |
| Symbol | TENX |
| Target High Price | 50.0 |
| Target Low Price | 26.0 |
| Target Mean Price | 34.875 |
| Target Median Price | 35.0 |
| Total Cash | 118,755,000 |
| Total Cash Per Share | 2.324 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.659425 |
| Two Hundred Day Average Change | 4.3205748 |
| Two Hundred Day Average Change Percent | 0.370565 |
| Type Disp | Equity |
| Volume | 1,284,770 |
| Website | https://www.tenaxthera.com |
| Zip | 27,517 |